Cynthia Gagnon1, Bernard Brais2, Isabelle Lessard2, Caroline Lavoie2, Isabelle Côté2, Jean Mathieu2. 1. From the Groupe de Recherche Interdisciplinaire sur les Maladies Neuromusculaires (GRIMN) (C.G., I.L., C.L., I.C., J.M.), Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay-Lac-Saint-Jean; Centre de Recherche Charles-Le Moyne-Saguenay-Lac-Saint-Jean sur les Innovations en Santé (C.G., I.L.), Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke; and Montreal Neurological Institute (B.B.), McGill University, Québec, Canada. cynthia.gagnon4@usherbrooke.ca. 2. From the Groupe de Recherche Interdisciplinaire sur les Maladies Neuromusculaires (GRIMN) (C.G., I.L., C.L., I.C., J.M.), Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay-Lac-Saint-Jean; Centre de Recherche Charles-Le Moyne-Saguenay-Lac-Saint-Jean sur les Innovations en Santé (C.G., I.L.), Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke; and Montreal Neurological Institute (B.B.), McGill University, Québec, Canada.
Abstract
OBJECTIVE: To develop a disease-specific severity index for adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) (DSI-ARSACS) that considers the 3 components (pyramidal, cerebellar, neuropathic) of the disease, and to document its content validity, internal consistency, and construct validity. METHODS: The Beta DSI-ARSACS (17 items) was developed based on literature review and expert inputs and then administered to 26 participants. Items reduction was based on Cronbach α and desirable criteria. Performance measures were administered to assess the construct validity of the final version of the DSI-ARSACS. RESULTS: The final DSI-ARSACS have 8 items that can be easily performed during usual medical follow-up. The mean score was 19.6 ± 8.1 (range 6.0-35.5) and the Cronbach α was 0.912. The DSI-ARSACS score increased with disease stage and age (p ≤ 0.001) and was closely correlated with other measures assessing similar construct (9-Hole Peg Test, 10-Meter Walk Test, Scale for the Assessment and Rating of Ataxia, Berg Balance Scale, Barthel Index) (r s = 0.75-0.95, p < 0.01). A moderate but not significant correlation was found with the 6-Minute Walk test (r s = -0.611, p = 0.108). CONCLUSIONS: The DSI-ARSACS is a valid measure of disease severity for the adult ARSACS population that is able to distinguish between patients with different clinical profiles. Further documentation of metrologic properties is necessary, but these first results are promising.
OBJECTIVE: To develop a disease-specific severity index for adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) (DSI-ARSACS) that considers the 3 components (pyramidal, cerebellar, neuropathic) of the disease, and to document its content validity, internal consistency, and construct validity. METHODS: The Beta DSI-ARSACS (17 items) was developed based on literature review and expert inputs and then administered to 26 participants. Items reduction was based on Cronbach α and desirable criteria. Performance measures were administered to assess the construct validity of the final version of the DSI-ARSACS. RESULTS: The final DSI-ARSACS have 8 items that can be easily performed during usual medical follow-up. The mean score was 19.6 ± 8.1 (range 6.0-35.5) and the Cronbach α was 0.912. The DSI-ARSACS score increased with disease stage and age (p ≤ 0.001) and was closely correlated with other measures assessing similar construct (9-Hole Peg Test, 10-Meter Walk Test, Scale for the Assessment and Rating of Ataxia, Berg Balance Scale, Barthel Index) (r s = 0.75-0.95, p < 0.01). A moderate but not significant correlation was found with the 6-Minute Walk test (r s = -0.611, p = 0.108). CONCLUSIONS: The DSI-ARSACS is a valid measure of disease severity for the adult ARSACS population that is able to distinguish between patients with different clinical profiles. Further documentation of metrologic properties is necessary, but these first results are promising.
Authors: T Schmitz-Hübsch; S Tezenas du Montcel; L Baliko; J Berciano; S Boesch; C Depondt; P Giunti; C Globas; J Infante; J-S Kang; B Kremer; C Mariotti; B Melegh; M Pandolfo; M Rakowicz; P Ribai; R Rola; L Schöls; S Szymanski; B P van de Warrenburg; A Dürr; T Klockgether; Roberto Fancellu Journal: Neurology Date: 2006-06-13 Impact factor: 9.910
Authors: Matthis Synofzik; Anne S Soehn; Janina Gburek-Augustat; Julia Schicks; Kathrin N Karle; Rebecca Schüle; Tobias B Haack; Martin Schöning; Saskia Biskup; Sabine Rudnik-Schöneborn; Jan Senderek; Karl-Titus Hoffmann; Patrick MacLeod; Johannes Schwarz; Benjamin Bender; Stefan Krüger; Friedmar Kreuz; Peter Bauer; Ludger Schöls Journal: Orphanet J Rare Dis Date: 2013-03-15 Impact factor: 4.123
Authors: Cynthia Gagnon; Olivier Lambercy; Christoph M Kanzler; Isabelle Lessard; Roger Gassert; Bernard Brais Journal: Ann Clin Transl Neurol Date: 2022-02-27 Impact factor: 4.511
Authors: Andreas Traschütz; Selina Reich; Astrid D Adarmes; Mathieu Anheim; Mahmoud Reza Ashrafi; Jonathan Baets; A Nazli Basak; Enrico Bertini; Bernard Brais; Cynthia Gagnon; Janina Gburek-Augustat; Hasmet A Hanagasi; Anna Heinzmann; Rita Horvath; Peter de Jonghe; Christoph Kamm; Peter Klivenyi; Thomas Klopstock; Martina Minnerop; Alexander Münchau; Mathilde Renaud; Richard H Roxburgh; Filippo M Santorelli; Tommaso Schirinzi; Deborah A Sival; Dagmar Timmann; Stefan Vielhaber; Michael Wallner; Bart P van de Warrenburg; Ginevra Zanni; Stephan Zuchner; Thomas Klockgether; Rebecca Schüle; Ludger Schöls; Matthis Synofzik Journal: Front Neurol Date: 2021-06-25 Impact factor: 4.003